| [1] |
Vigil D,Cherfils J,Rossman KL,et al.Ras superfamily GEFs and GAPs:validated and tractable targets for cancer therapy[J].Nat Rev Cancer,2010,10(12):842-857.
|
| [2] |
Goitre L,Trapani E,Trabalzini L,et al.The Ras superfamily of small GTPases:the unlocked secrets[J].Methods Mol Biol,2014,1120(12):1-18.
|
| [3] |
Bos JL.Ras oncogenes in human cancer:a review[J].Cancer Res,1989,49(17):4682-4689.
|
| [4] |
Adjei AA.Blocking oncogenic Ras signaling for cancer therapy[J].J Natl Cancer Inst,2001,93(14):1062-1074.
|
| [5] |
Takashima A, Faller DV. Targeting the RAS oncogene[J].Expert Opin Ther Targets,2013,17(5):507-531.
|
| [6] |
Marciano D,Ben-Baruch G,Marom M,et al.Farnesyl derivatives of rigid carboxylic acids inhibitors of ras-dependent cell growth[J].J Med Chem,1995,38(8):1267-1272.
|
| [7] |
Riely GJ,Johnson ML,Medinaetal C,et al.A phase II trial of salirasib in patients with lung adenocarcinomas with KRAS mutations[J].J Thorac Oncol,2011,6(8):1435-1437.
|
| [8] |
Charette N,De Saeger C,Horsmans Y,et al.Salirasib sensitizes hepatocarcinoma cells to TRAIL-induced apoptosis through DR5 and survivin-dependent mechanisms[J].Cell Death Disease,2013,4(1):e471.
|
| [9] |
Mologni L,Brussolo S,Ceccon M,et al.Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells[J].PLoS One,2012,7(12):e51449.
|
| [10] |
Haklai R,Elad-Sfadia G,Egozi Y,et al.Orally administered FTS(salirasib)inhibits human pancreatic tumor growth in nude mice[J].Cancer Chemother Pharmacol,2008,61(1):89-96.
|
| [11] |
St Jean DJ Jr,Fotsch C.Mitigating heterocycle metabolism in drug discovery[J].J Med Chem,2012,55(13):6002.
|
| [12] |
Ling Y,Wang ZQ,Zhu HY,et al.Synthesis and biological evaluation of farnesylthiosalicylamides as potential anti-tumor agents[J].Bioorg Med Chem,2014,22(1):374-380.
|
| [13] |
Wang ZQ,Wang XM,Zhang W,et al.Synthesis and biological evaluation of novel farnesylthiosalicylic acid/hydroxylcinnamic acid hybrids as potential anti-tumor agents[J].J China Pharm Univ(中国药科大学学报),2014,45(3):392-399.
|
下载:
